The alternatives
Curex scores 87/100 (grade B+, ranked #15) on The Verdict Score. Here are the top-rated GLP-1 providers we'd weigh against it — same six-factor rubric, and no score is adjusted for payment.
Curex — FDA warning letter, September 2025. Addressed to Curex, and public in FDA’s warning-letter database.
The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
CoreAge Rx scores 94/100 to Curex's 87, and our Curex vs CoreAge Rx ruling sets the two out factor by factor.
A LegitScript-verified nationwide operator that pairs fair compounded pricing with real brand-name access.
Effecty matches Curex at 87/100; our Effecty ruling in full has the pricing conditions and the caveats in detail.
A heavyweight telehealth brand with brand-name access and a polished experience — but opaque compounded pricing.
Ro matches Curex at 87/100; our Ro ruling in full has the pricing conditions and the caveats in detail.
Carries one of the deepest published catalogs in the ranking — compounded semaglutide and tirzepatide plus needle-free oral and microdosed routes, PT-141, intranasal NAD+ and a wall of recovery peptides — and backs it with a checkable LegitScript certification and HIPAA compliance, but the verdict docks it hard because every line is compounded, not FDA-approved, and the pricing turns opaque the moment you look past the headline GLP-1 tiers.
Telos Rx scores 85/100 to Curex's 87; the full Telos Rx review has the pricing conditions and the caveats in detail.
One of the rare compounded programs that puts its price on the page — $199 semaglutide and $299 tirzepatide, both molecules, nationwide — wrapped in a broader longevity menu, but the verdict holds it at mid-pack because everything is compounded, injectable-only, and the 50-state and results claims are self-reported with a thin independent track record.
yourEra scores 84/100 to Curex's 87; our full write-up on yourEra has the pricing conditions and the caveats in detail.
Earns its keep on pricing transparency — every tier is published, dose-flat and includes combo and microdose options — but the verdict holds it back for a compounded-only formulary and a state map it won't show.
Enhance MD scores 85/100 to Curex's 87; our full write-up on Enhance MD has the pricing conditions and the caveats in detail.
The only program here selling the same molecule as a lozenge or an injection at the same price — the needle is genuinely optional, though the company carries an FDA warning letter from February 2026.
Strut Health scores 84/100 to Curex's 87; our Strut Health ruling in full has the pricing conditions and the caveats in detail.
See the complete rankings or head to the comparison hub.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Not medical advice; see our disclosure.